Clinical Trials Browser

INDUSTRY × pemigatinib × Tumor-Agnostic × Clear all

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT04003623 2022-05-10

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Phase 2 Terminated

1 enrolled 2 charts

Neoplasm Metastasis